Arizona
Tucson; University of Arizona Cancer Center/Arizona Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
California
Duarte; City of Hope
SWOG E1697: Phase III Randomized Study of Four Weeks of High Dose IFN-a2b in Stage T3 - T4 or N1 (microscopic) Melanoma
Duarte; City of Hope National Medical Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Duarte; City of Hope
Medarex MDX010-20: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A*0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
La Jolla; UCSD Moores Cancer Center
A clinical study evaluating the efficacy, safety, and tolerability of OncoVEX in subjects with inoperable melanoma.
La Verne; Research Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Laverne; Research Site
A Randomized, Double-Blind, Multi-Center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Long Beach; Pacific Shores Medical Group
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Los Angeles; USC/Norris Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Orange; St Joseph Hospital
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Riverside; Kaiser Permanente
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
San Diego ; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
San Diego; Scripps Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
San Francisco; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
San Francisco; Northern California Melanoma Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Santa Monica; Cancer Institute Medical Group, Inc.
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Santa Monica; Local Institution
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Santa Monica; Research Site
A Randomized, Double-Blind, Multi-Center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Vallejo; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Vista; San Diego Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Colorado
Aurora; University of Colorado Cancer Center, Anschutz Cancer Pavilion
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Boulder; Rocky Mountain Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Colorado Springs; Rocky Mountain Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Denver; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Denver; Rocky Mountain Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Florida
Hollywood; Memorial Regional Hospital/Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Jacksonville; University of Florida Health Science Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Miami; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Miami; University of Miami Hospital & Clinics/SCCC
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Miami; Research Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Miami Beach; Mount Sinai Medical Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Orlando; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
West Palm Beach; Palm Beach Cancer Institute
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Georgia
Atlanta; Emory University Hospital
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Illinois
Chicago; Rush University Medical Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Chicago; Local Institution
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Decatur; Decatur Memorial Hospital/Clinical Research
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Maywood; Loyola University Chicago Cardinal Bernardin Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Indiana
Goshen; Goshen Center for Cancer Care
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Indianapolis; Indiana Oncology & Hematology Consultants
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Indianapolis; Research Site
A Randomized, Double-Blind, Multi-Center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Kentucky
Hazard; Local Institution
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Lexington; Central Baptist Hospital
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Louisville; University of Louisville
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Maryland
Baltimore; Johns Hopkins Unv., School of Medicine
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
Baltimore; Johns Hopkins Unv. School of Med., Sidney Kimmel Comprehensive Cancer Center
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
Baltimore; Franklin Square Hospital Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Baltimore; Research Site
A Randomized, Double-Blind, Multi-Center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Lutherville; Sidney Kimmel Comprehensive Cancer Center at John Hopkins
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Massachusetts
Boston; Beth Isreal Deaconess Medical Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Michigan
Detroit; Henry Ford Health System
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
Detroit; Henry Ford Health Systems
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Detroit; Henry Ford Health System
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Minnesota
Robbinsdale; Hubert H. Humphrey Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Robbinsdale; Hubert H Humphrey Cancer Center
A clinical study evaluating the efficacy, safety, and tolerability of OncoVEX in subjects with inoperable melanoma.
Rochester; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Missouri
Columbia ; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Columbia; University of Missouri
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
St. Joseph; St. Joseph Oncology
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
St. Louis; Washington University School of Medicine - Barnes Jewish Hospital
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
St. Louis; Washington University School of Medicine
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
St. Louis; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Nevada
Las Vegas; Local Institution
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
New Jersey
Hackensack; The Cancer Center, Hackensack University Medical Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Montclair; Mountainside Hospital
A clinical study evaluating the efficacy, safety, and tolerability of OncoVEX in subjects with inoperable melanoma.
Morristown; Hematology -Oncology Associates of NNJ-PA
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
New Brunswick; The Cancer Center of NJ
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Summit; Summit Medical Group Overlook CC
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
New Mexico
Albuquerque; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
New York
East Synacuse; Research Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
East Syracuse; Hematology-Oncology Associates of CNY
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
New York; Columbia University Medical Center
This study involves the injection of certain peptides and an immune system stimulating substance to try to stimulate the immune system to recognize and kill melanoma tumor cells.
New York; Columbia-Presbyterian Medical Center
A phase II study of a 4-hour schedule of Temozolomide in the treatment of patients with advanced melanoma.
New York; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
New York; Memorial Sloan-Kettering Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
New York; Columbia University Medical Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
New York; Biomedical Research Alliance of New York
A clinical study evaluating the efficacy, safety, and tolerability of a study drug in subjects with advanced melanoma.
New York; Columbia University
A clinical study evaluating the efficacy, safety, and tolerability of OncoVEX in subjects with inoperable melanoma.
New York; Biomedical Research Alliance of New York
A clinical study comparing standard treatment for advanced melanoma to an experimental study drug.
Rochester; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
North Carolina
Charlotte; Blumenthal Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Huntersville; Carolina BioOncology Institute, PLLC
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
Ohio
Cincinnati; The Christ Hospital
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Cleveland; Cleveland Clinic Foundation
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Dayton; Dayton Clinical Oncology Program
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Oregon
Portland; Providence Portland Medical Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Portland; Local Institution
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Pennsylvania
Hershey; Penn State Cancer Institute @Milton S. Hershey Medical Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Philadelphia; University of Pennsylvania- Abramson Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Philadelphia; Fox Chase Cancer Center, CRU2nd Floor
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Philadelphia; Thomas Jefferson University/Kimmel Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Pittsburg; University of Pittsburg Cancer Institute/Hillman Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Pittsburgh; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Rhode Island
Providence; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
South Carolina
Easley; Cancer Centers of the Carolinas
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Greenville; Cancer Centers of the Carolinas
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Greenville; Cancer Centers of the Carolinas
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Seneca; Cancer Centers of the Carolinas
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Spartanburg; Cancer Centers of the Carolinas
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Tennessee
Memphis ; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Memphis; Research Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Nashville; Vanderbilt-Ingram Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Texas
Arlington; Arlington Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Arlington; Research Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Dallas; Mary Crowley Medical Research Center
A clinical study evaluating the efficacy, safety, and tolerability of OncoVEX in subjects with inoperable melanoma.
Dallas; Research Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplatons A10 And AS2-1 In Patients With Malignant Melenoma
Lubbock; Joe Arrington Cancer and Research & Treatment Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Tyler; Tyler Cancer Center
A clinical study evaluating the efficacy, safety, and tolerability of OncoVEX in subjects with inoperable melanoma.
Utah
Salt Lake City; Huntsman Cancer Institute
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Vermont
Burlington; Fletcher Allen Health Care
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Virginia
Charlottesville; University of Virginia
Evaluation of the Effects of Local GM-CSF-in-adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes ( HIC # 8380)
Charlottesville; University of Virginia
Phase II Trial for the Evaluation of the Efficacy of Vaccination with Synthetic Melanoma Peptides Administered with GM-CSF-in-adjuvant in Patients with Advanced Melanoma HIC #10049
Charlottesville; University of Virginia
Adults with Melanoma Sought for Clinical Trial
Norfolk; Virginia Oncology Associates
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Norfolk; Research Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Washington
Seattle; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
International
Buenos Aires, Argentina; Hospital General de Agudos Carlos G. Durand
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Buenos Aires, Argentina; Hospital Militar Central
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Buenos Aires, Argentina; Hospital Britanico de Buenos Aires
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Buenos Aires, Argentina; Hospital Municipal de Oncologia Maria Curie
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Cordoba, Argentina; Hospital Privado de Cordoba S.A.
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
La Plata, Argentina; Instituto Medico Platense
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Provincia de Buenos Aires, Argentina; Instituto Medico
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Provincia de Santa Fe, Santa Fe, Argentina; ISIS Clinica Especializada
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Nedlands, Australia; Sir Charles Gairdner Hospital
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
South Brisbane, Qld, Australia; Mater Adult Hospital
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Waratah, NSW, Australia; Newcastle Melanoma Unit
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Wodonga, Vic, Australia; Murray Valley Private Hospital and Cancer Treatment Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Wien, Austria; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Bruselles, Belgium; Institut Jules Bordet
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Goiana, GO, Brazil; Associacao de Combate ao Cancer de Goias
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Londrina, PR, Brazil; Pro-Onco Centro De Tratamento Oncologico S/C Ltda
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Porto Alegre, RS, Brazil; Fundacao Central Sul-Americana para o Desenvolvimento de Novas Drogas
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Santo Andre, SP, Brazil; Santo Andre Diagnosticos e Tratamentos Ltda
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Sao Paulo, SP, Brazil; Hospital das Clinicas-Faculdade de Medicina da Universidade de Sao Paulo
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Sao Paulo, SP, Brazil; Sociedade Baneficente de Senhoras - Hospital
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Calgary , Alberta, Canada; Tom Baker Cancer Center
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Calgary, AB, Canada; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Edmonton, AB, Canada; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Edmonton, AL, Canada; Cross Cancer Institute
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Edmonton, Alberta, Canada; Cross Cancer Institute
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
London, Ontario, Canada; London Regional Cancer Program
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Montreal, QC, Canada; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
St. John's, Newfoundland, Canada; The Dr. H. Bliss Murphy
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Winnipeg, Manitoba, Canada; St. Boniface Hospital
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Winnipeg, Manitoba, Canada; St. Boniface Hospital
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Renaca, Chile; Clinica Renaca
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Santiago, Chile; Clinica Davila
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Santiago, Chile; Instituto Nacional del Cancer
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Santiago, Chile; Fundacion Arturo Lopez Perez
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Santigo, Chile; Clinica Davila
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Bordeaux, France; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Lille Cedex, France; Service d'oncologie medicale
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Lyon Cedex 8, France; Depertment de Cancerlolgie
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Marseille, France; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Nantes, France; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Rennes cedex, France; Service d'oncologie Medicale
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Vandoeuvre les Nancy, France; Centre Alexis Vautrin
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Augsburg, Germany; Klinik f. Dermatologie
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Berlin, Germany; Charite-Universitaets
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Berlin, Germany; Charite-Universitaets
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Erlangen, Germany; Poliklinik fur Kinder und Jugendliche
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Essen, Germany; Universitatsklinikum Essen
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Heidelberg, Germany; Universitatsklinikum Heidelberg
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Jena, Germany; Klinikum der Friedrich - Schiller- Universitat Jena
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Kiel, Germany; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Kiel, Germany; Universitatsklinukum Schleswig-Holstein
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Mannheim, Germany; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Mannheim, Germany; Universitatsklinikum Mannheim
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Regensburg, Germany; Klinikum der Universitat Regensburg
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Tubingen, Germany; Universitatsklinikum Tubingen
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Tübingen, Germany; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Wurzburg, Germany; Universitatsklinikum Wurzburg
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Firenze, Italy; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma.
Genova, Italy; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma.
Milano, Italy; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Dacarbazine in Patients With Unresectable/Metastatic Melanoma.
Milano, Italy; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma.
Milano, Italy; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Napoli, Italy; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma.
Siena, Italy; Local Institution
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Torino, Italy; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma.
Rotterdam, Netherlands; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Rayazan, Russian Federation; Local Institution
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Voronezh, Russian Federation; Local Institution
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Groenkloof, Praetoria, S. Africa; Mary Potter Oncology Centre
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Johannesburg, Gauteng, S. Africa; The Medical Oncology Centre of Rosebank
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Panorama, S. Africa; GVI Oncology
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Port Elizabeth, S. Africa; Eastern Cape Oncology Centre
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Sandton, S. Africa; Sandton Oncology
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Pretoria, South Africa; Wilgers Oncology Centre
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Madrid, Spain; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Valencia, Spain; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Zürich, Switzerland; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Amsterdam, The Netherlands; Vrije Universiteit Medisch Centrum (VUMC)
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Glasgow, United Kingdom; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Leeds, United Kingdom; St. James University Hospital
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Northwood, United Kingdom; Research Site:
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
Barretos, SP, USA; Hospital de Cancer de Barretos - Fundacao
Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
